Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of acute myeloid leukemia. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations, interactive polling of attendees using keypad devices and follow-up audience Q&A.
If you are interested in hosting a session at your institution, please email our Meeting Services Department at GRTeam@ResearchToPractice.com or call (800) 233-6153.
Schedule of Events
Monday, March 30, 2020
12:00 PM – 1:00 PM
Education program
Faculty
Richard M Stone, MD |
Mercy Medical Center
Springfield, Massachusetts
Box lunch will be provided
|
Registration is open only to oncology professionals from this institution and invited guests.
Email us for more information. |
Thursday, April 9, 2020
5:00 PM – 6:00 PM
Education program
Faculty
Mark Levis, MD, PhD |
SUNY Upstate Medical University
Syracuse, New York
Buffet dinner will be provided
|
Registration is open only to oncology professionals from this institution and invited guests.
Email us for more information. |
Friday, May 1, 2020
12:00 PM – 1:00 PM
Education program
Faculty
Eytan M Stein, MD |
Watson Clinic Cancer and Research Center
Lakeland, Florida
Buffet lunch will be provided
|
Registration is open only to oncology professionals from this institution and invited guests.
Email us for more information. |
Friday, May 22, 2020
12:00 PM – 1:00 PM
Education program
Faculty
Daniel A Pollyea, MD, MS |
Community Cancer Institute
Clovis, California
Buffet lunch will be provided
|
Registration is open only to oncology professionals from this institution and invited guests.
Email us for more information. |
There is no registration fee for these events. However, preregistration is advised as seating is limited.
Each 1-hour session will include 5 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for acute myeloid leukemia (AML). Each event will employ an identical format that will include the following elements:
- Discussion of Steering Committee Members’ Treatment Recommendations
- Review of Available Clinical Research Findings
- Integration of Interactive Audience Polling Results
MODULE 1 Contemporary Biomarker Assessment
MODULE 2 Bcl-2 Inhibition as a Rational Therapeutic Strategy in AML
MODULE 3 Recently Approved and Emerging Therapeutic Options for Patients with AML and a FLT3 Mutation
MODULE 4 Contemporary Management of AML with an IDH Mutation
MODULE 5 Other Recently Approved and Imminent Compounds
Each session will conclude with a 5-minute Q&A segment
STEERING COMMITTEE MEMBERS
Harry P Erba, MD, PhD
Professor, Department of Medicine
Director of the Leukemia Program
Division of Hematologic Malignancies and
Cellular Therapy
Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina
Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
Daniel A Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Robert H Allen, MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado
Keith W Pratz, MD
Associate Professor of Medicine
Director of Leukemia Program
University of Pennsylvania
Philadelphia, Pennsylvania
Eytan M Stein, MD
Assistant Attending Physician
Director, Center for Drug Development in Leukemia
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Richard M Stone, MD
Chief of Staff
Director, Translational Research
Leukemia Division
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Wendy Stock, MD
Anjuli Seth Nayak Professor of
Leukemia Research
University of Chicago Medicine
Chicago, Illinois
Project Chair
Neil Love, MD
President
Research To Practice
Miami, Florida
Target Audience
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).
Learning Objectives
- Understand the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to develop, adapt or refine diagnostic testing algorithms for patients with AML.
- Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of AML.
- Recognize the FDA approval of venetoclax for patients with newly diagnosed AML unfit for intensive therapy, and discern how this agent can be optimally integrated into nonresearch care algorithms.
- Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
- Develop an understanding of the mechanism of action of, available data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or 2 mutation.
- Appreciate the mechanism of action of, available clinical trial data with and FDA-endorsed indication for glasdegib, and identify patients appropriate for therapeutic intervention with this agent.
- Design and implement a plan of care to prevent, recognize and manage side effects and toxicities associated with the use of recently approved systemic therapies in the management of AML to support quality of life and continuation of therapy.
- Identify the mechanisms of action of and recall new data with investigational agents demonstrating promising activity in AML, and refer appropriate patients for participation in ongoing trials evaluating these approaches.
CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.
Commercial Support
These activities are supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc and Astellas.
|
